Costs of Inflammatory markers worldwide and the use of Butyrylcholinesterase (BChE)
Authors:
- Emiljan MustaqeEMEmiljan Mustaqe
- Elias LiolisELElias Liolis
- Eleni BekouEBEleni Bekou
- Levan TchabashviliLTLevan Tchabashvili
- Konstantinos TasiosKTKonstantinos Tasios
- Andreas AntzoulasAAAndreas Antzoulas
- Dimitrios LitsasDLDimitrios Litsas
- Panagiotis LeventisPLPanagiotis Leventis
- Viola TzafaiVTViola Tzafai
- Platon DimopoulosPDPlaton Dimopoulos
- Vasileios LeivaditisVLVasileios Leivaditis
- Francesk MulitaFrancesk Mulita
Open Access
- 16 December 2024
- journal article
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 11 (12) , 399-401
Abstract
Objective: Butyrylcholinesterase (BChE) is an enzyme that shares similarities with acetylcholinesterase (AChE) but has been less studied due to its uncertain physiological role. Initially regarded as an ‘orphan enzyme,’ recent studies suggest that BChE plays a significant role in inflammation, primarily through its involvement in the cholinergic anti-inflammatory pathway. This enzyme, primarily produced by the liver, is found in several tissues and is known to hydrolyze acetylcholine, a neurotransmitter that modulates immune responses. BChE levels are influenced by various diseases, such as diabetes, cardiovascular diseases, and neurological disorders, which are associated with inflammation. This study reviews the costs of inflammatory biomarkers worldwide and investigates the association between BChE and inflammation. Data from multiple countries reveal varying costs for biomarkers like C-reactive protein (CRP), procalcitonin (PCT), and BChE, with BChE being a more cost-effective option in certain regions such as Greece and Armenia. Furthermore, BChE activity correlates inversely with the degree of systemic inflammation, and its levels may serve as a predictive marker for conditions such as surgical infections and anastomotic leaks. The findings underscore the potential of BChE as a useful and affordable biomarker for monitoring inflammation, particularly in settings where other biomarkers are more costly. However, further research is needed to validate its widespread clinical application.Keywords
This publication has 13 references indexed in Scilit:
- Diagnoses of Pathological States Based on Acetylcholinesterase and ButyrylcholinesteraseCurrent Medicinal Chemistry, 2020
- Reduced serum cholinesterase activity indicates splenic modulation of the sterile inflammationJournal of Surgical Research, 2017
- Reduced butyrylcholinesterase activity is an early indicator of trauma-induced acute systemic inflammatory responseJournal of Inflammation Research, 2016
- Reduced Serum Butyrylcholinesterase Activity Indicates Severe Systemic Inflammation in Critically Ill PatientsMediators of Inflammation, 2015
- Cholinesterases as Biomarkers for Parasympathetic Dysfunction and Inflammation-Related DiseaseJournal of Molecular Neuroscience, 2013
- MicroRNA-132 Modulates Cholinergic Signaling and Inflammation in Human Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Association between butyrylcholinesterase activity and low-grade systemic inflammationAnnals of Hepatology, 2012
- Inflammatory Mechanisms: The Molecular Basis of Inflammation and DiseaseNutrition Reviews, 2007
- THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY FROM THE BRAIN TO THE SERUM.Shock, 2004
- Neurobiology of butyrylcholinesteraseNature Reviews Neuroscience, 2003